Lab monkey prices plunge in China as drug research slows
中国实验猴价格暴跌，反映新药研发放缓
Pharmaceutical companies scale back development in aftermath of pandemic
新冠疫情期间，随着药物研发投资激增，实验用猴在中国的价格达到每只2.6万美元的峰值，去年底它们的价格下降到每只1.1万美元。
Lab monkey prices in China have plummeted as a post-pandemic slowdown in drug development ripples through the pharmaceutical sector in the world’s second-largest economy.
实验用猴在中国的价格已大幅下跌，原因是新冠疫情过后，这个世界第二大经济体的医药行业出现了药物研发放缓的情况。
The price of so-called non-human primates in China — an indicator of the future pipeline of drugs undergoing clinical trials — hit a peak of $26,000 per animal in 2022, up from $4,000 in 2019. But by the end of last year, it had fallen to $11,000, according to UBS data.
在中国，所谓的“非人灵长类动物”的价格——反映未来可进入临床试验阶段的药物研发管线的指标——在2022年达到每只2.6万美元的峰值，远高于2019年的每只4000美元。但到去年年底，根据瑞银(UBS)的数据，它们的价格下降到每只1.1万美元。
